Integrity Coronary Stent System    

Log In

Forgot Your Password?

Not a member? Click here!

Drug-Eluting Stents in AMI: A Proven Strategy?
Arguing for Routine Upstream GP IIb/IIIa Inhibitors in ACS and NSTEMI: How Early Should We Give Them?
Low-Molecular Weight Heparins in ACS: New Insights from SYNERGY, STEEPLE and EXTRACT
Fondaparinux in ACS
Insights to Factors Affecting Response to Aspirin and Clopidogrel: Interactions with other Medications and Platelet Turnover Rate



DES Prove Equally Effective in Octogenerians

The safety and efficacy of DES remains uncertain in the elderly as randomized studies often have excluded such patients. The XIMA Trial has demonstrated that, as compared with the Vision BMS, everolimus-eluting stents are associated with a lower incidence of MI and TVR with no increased risk of major bleeding.

For more, click here




RIBS V Favours EES in ISR

The optimal strategy for the treatment of in-stent restenosis is yet to be determined. The RIBS V trial compared a strategy of stenting with everolimus-eluting stents (EES) with drug-eluting balloons (DEB) in patients presenting with bare-metal in-stent restenosis. The study has demonstrated that although both treatments are effective, EES lead to superior late angiographic findings.

For more, click here




Leadless Pacing

Traditional cardiac pacemakers may develop long-term complications related to either the lead and/or the generator. A trial of a self-contained, single chamber, leadless cardiac pacemaker has shown the device to be safe and feasible at 90 days follow-up.

For more, click here




The Enigma of Lytics in Pulmonary Embolism

The role of fibrinolytic therapy in intermediate-risk pulmonary embolism (IRPE) has remained controversial. A randomized study of 1005 patients has demonstrated that although fibrinolysis may prevent hemodynamic decompensation in patients presenting with IRPE, this treatment is associated with significant risks of major haemorrhage and stroke.

For more, click here



Untitled Document
2013 ACS: Year in Review
- Robert P. Giugliano, MD
CoreValve US Pivotal Trials
- Michael J. Reardon, MD
IN.PACT SFA - Randomized Trial of IN.PACT Admiral DCB vs. PTA for the Treatment of Atherosclerotic Lesions in the SFA and/or PPA: 1-year Primary Outcomes
- Gunnar Tepe, MD
Dual Antiplatelet Therapy (DAPT) Duration Dilemma: Recent Trials And Guidelines For Clinical Practice
- Dean J. Kereiakes, MD
Coronary microvascular dysfunction
- Filippo Crea, MD

Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD

Josep Rodés-Cabeau, MDAntithrombotic treatment in TAVI
- Josep Rodés-Cabeau, MD
 Click here to visit the WEBEX archives

Obesity and Cardiovascular Diseases: Implications Regarding Fitness, Fatness, and Severity in the Obesity Paradox.
C Lavie, et al.
JACC 2014; 63:1345-1354
Mechanisms, Pathophysiology, and Clinical Aspects of Incomplete Stent Apposition.
G Attizzani, et al.
JACC 2014; 63:1355-1367
A Prospective Randomized Trial of Everolimus-Eluting Stents Versus Bare-Metal Stents in Octogenarians. The XIMA Trial (Xience or Vision Stents for the Management of Angina in the Elderly).
A de Belder, et al.
JACC 2014; 63:1371-1375
A Randomized Comparison of Drug-Eluting Balloon Versus Everolimus-Eluting Stent in Patients With Bare-Metal Stent–In-Stent Restenosis. The RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs. Everolimus-eluting Stent).
F Alfonso, et al.
JACC 2014; 63:1378-1386
Permanent Leadless Cardiac Pacing. Results of the LEADLESS Trial.
V Reddy, et al.
Circ 2014; 129:1466-1471
Temporal Trends in Ischemic Heart Disease Mortality in 21 World Regions, 1980 to 2010. The Global Burden of Disease 2010 Study.
A Moran, et al.
Circ 2014; 129:1483-1492
Racial and Regional Differences in Venous Thromboembolism in the United States in 3 Cohorts.
N Zakai, et al.
Circ 2014; 129:1502-1509
Spironolactone for Heart Failure with Preserved Ejection Fraction.
B Pitt, et al.
NEJM 2014; 370:1383-1392
A Controlled Trial of Renal Denervation for Resistant Hypertension.
D Bhatt, et al.
NEJM 2014; 370:1393-1401
Validation of the Atherosclerotic Cardiovascular Disease Pooled Cohort Risk Equations.
P Muntner, et al.
JAMA 2014; 311:1406-1415
Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort.
M Kavousi, et al.
JAMA 2014; 311:1416-1423

Poll Archives

CRYSTAL AF: Long-Term Follow-Up Results
Rod S. Passman, MD, et al.
A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis Deemed High-Risk for Surgery
David H. Adams, MD
Results of the SYMPLICITY HTN 3 Trial
Deepak L. Bhatt, MD, MPH, et al.
Four-Year Outcomes Following Resolute Zotarolimus-Eluting Stent Implantation: RESOLUTE US Study
David Lee, MD, et al.
Does IVUS Have Any Role in Evaluating Intermediate Lesions?
Ron Waksman, MD
The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension
Michael Böhm, MD
Adeel Shahzad, MD, et al.
(GIPS)-III trial
Chris P.H. Lexis, MD, et al.
Results of the MSC-HF Trial
Anders Bruun Mathiasen, MD
The NOBORI Biolimus-Eluting versus XIENCE/PROMUS Everolimus-eluting Stent Trial (NEXT)
Masahiro Natsuaki, MD
A Subanalysis of the OPTIMIZE Clinical Trial
Fausto Feres, MD, et al.
OPTIMIZE Clinical Trial
Ricardo A. Costa, MD, et al.
POISE-2 Trial - Aspirin in Patients Undergoing Noncardiac Surgery
PJ Devereaux, MD
ZEUS Trial
M. Valgimigli, MD, PhD
Philip R Schauer, MD, PhD
SIRS Trial
Population Health Research Institute
Patterns of Left Ventricular Remodeling in Patients with Severe Aortic Stenosis in The PARTNER Trial
Sammy Elmariah, MD
Outcomes of Inoperable Patients Undergoing Transapical and Transaortic Transcatheter Aortic Valve Replacement
Mathew Williams, MD
A Randomized Comparison of Vascular Complications after TAVR Comparing the SAPIEN vs. The Lower-Profile SAPIEN XT System in Inoperable Aortic Stenosis Patients
Augusto D. Pichard, MD
30 Day Outcomes from The PARTNER II Trial for Transapical and Transfemoral 29mm TAVR in Inoperable Patients with the Edwards SAPIEN XT
Vasilis Babaliaros, MD
Costs of Periprocedural Complications in Patients Treated with Transcatheter Aortic Valve Replacement
Suzanne V. Arnold, MD
Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses
John Webb, MD, et al.

Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
Stephan Windecker, MD, et al.

Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD
The RESOLUTE Program: today and tomorrow
Sigmund Silber, MD, PhD
RESOLUTE International Trial
F-J. Neumann, MD, et al.
Primary Results Following Percutaneous Coronary Intervention with the 38mm Resolute Zotarolimus-eluting Stent
Shirish Hiremath, MD, et al.
Two Year Outcomes Following Implantation of the Resolute Zotarolimus-eluting Stent in Small (less or equal to 2.5 mm) Vessels
Ronald Caputo, MD

Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2013 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login

Copyright © 2014, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb